文献速递慢性肾脏病肾血管病与高血压

靶向白细胞介素-6治疗慢性肾脏病与心血管疾病

Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease.
PubMed 文献 · Kidney Int Rep · 2026-07-21

本综述探讨白细胞介素-6(IL-6)通路在慢性肾脏病(CKD)和心血管疾病(CVD)发生发展中的作用,汇总IL-6上调的临床证据及其对肾脏和心血管结局的影响,并概述抗炎治疗(包括IL-6抑制剂)的进展与未来研究方向。

要点

  • IL-6通路介导的炎症在CKD和CVD的发生与进展中起重要作用。
  • 需进一步研究明确靶向抗炎治疗在CKD和CVD中的疗效与长期安全性。
  • IL-6抑制剂等抗炎治疗是CKD和CVD的潜在治疗方向。

核心结论

  • IL-6通路是CKD和CVD共享的重要炎症机制,靶向IL-6的抗炎治疗是潜在方向,但其疗效和长期安全性尚待研究确立。

研究设计与样本

  • 综述类文章,检索范围未在摘要中具体报告。

主要发现

  • IL-6通路介导的炎症在CKD和CVD的发生和进展中起重要作用。
  • CKD和CVD存在多种共享的病理生理危险因素且常共存。
  • 标准治疗在减轻炎症相关风险方面存在局限性。
  • 抗炎治疗(包括在研IL-6抑制剂)已取得近期进展。

临床怎么用

  • 关注IL-6通路作为CKD和CVD共享炎症靶点的潜在价值。
  • 在CKD和CVD管理中重视炎症相关风险的评估与干预。

局限性

  • 靶向抗炎治疗在CKD和CVD中的疗效和长期安全性尚未确立,需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple shared pathophysiological risk factors and often coexist. Inflammation, particularly mediated by the interleukin-6 (IL-6) pathway, plays an important role in the development and progression of both conditions. In this review, we examine the mechanisms of IL-6 production and signaling and summarize clinical evidence for IL-6 upregulation in CKD and CVD. We discuss the impact of IL-6 on kidney and cardiovascular outcomes, the interplay between CKD, CVD, and associated complications, and the limitations of standard-of-care strategies in attenuating risks related to the presence of inflammation. We also provide an overview of recent advances in anti-inflammatory therapies, including IL-6 inhibitors in development. Finally, we highlight future research directions that are required to establish the efficacy and long-term safety of targeted anti-inflammatory therapies in CKD and CVD.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Cherney DZ, Pecoits-Filho R, et al. Targeting Interleukin-6 for Treatment of CKD and Cardiovascular Disease. Kidney Int Rep. 2026. PMID: 42656828. doi:10.1016/j.ekir.2026.106712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。